Reversible corticotropin releasing factor receptor 1 (CRF1
) antagonist (Ki
values are 3.4 and 7.9 nM at rat and human CRF1
respectively) that displays >1000-fold selectivity over CRF2
receptors. Suppresses CRF-induced ACTH release in vitro
= 241 nM) and is brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
PET imaging of CRF1 with [11C]R121920 and [11C]DMP696: Is the target of sufficient density?
Sullivan et al.
Synthesis and in vivo evaluation of [11C]SN003 as a PET ligand for CRF1 receptors.
Kumar et al.
Pharmacological characterization of a novel nonpeptide antagonist radioligand, (±)-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for cortic
Zhang et al.